These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 23754138

  • 1. Newer treatments in the management of pediatric asthma.
    Robinson PD, Van Asperen P.
    Paediatr Drugs; 2013 Aug; 15(4):291-302. PubMed ID: 23754138
    [Abstract] [Full Text] [Related]

  • 2. Pediatric asthma: guidelines-based care, omalizumab, and other potential biologic agents.
    Huffaker MF, Phipatanakul W.
    Immunol Allergy Clin North Am; 2015 Feb; 35(1):129-44. PubMed ID: 25459581
    [Abstract] [Full Text] [Related]

  • 3. Omalizumab for asthma: indications, off-label uses and future directions.
    Ben-Shoshan M.
    Recent Pat Inflamm Allergy Drug Discov; 2010 Nov; 4(3):183-92. PubMed ID: 20807194
    [Abstract] [Full Text] [Related]

  • 4. Anti-IgE for chronic asthma in adults and children.
    Walker S, Monteil M, Phelan K, Lasserson TJ, Walters EH.
    Cochrane Database Syst Rev; 2006 Apr 19; (2):CD003559. PubMed ID: 16625585
    [Abstract] [Full Text] [Related]

  • 5. Omalizumab for severe asthma: efficacy beyond the atopic patient?
    Domingo C.
    Drugs; 2014 Apr 19; 74(5):521-33. PubMed ID: 24691707
    [Abstract] [Full Text] [Related]

  • 6. The impact of asthma exacerbations and preventive strategies.
    Graham LM, Eid N.
    Curr Med Res Opin; 2015 Apr 19; 31(4):825-35. PubMed ID: 25530129
    [Abstract] [Full Text] [Related]

  • 7. A proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma.
    Garcia G, Magnan A, Chiron R, Contin-Bordes C, Berger P, Taillé C, Devouassoux G, de Blay F, Couderc LJ, Didier A, O'Callaghan DS, Girodet PO, Bourdeix I, Le Gros V, Humbert M.
    Chest; 2013 Aug 19; 144(2):411-419. PubMed ID: 23579324
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.
    Maselli DJ, Singh H, Diaz J, Peters JI.
    Ann Allergy Asthma Immunol; 2013 Jun 19; 110(6):457-61. PubMed ID: 23706716
    [Abstract] [Full Text] [Related]

  • 11. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I, Vidaurre CF.
    J Allergy Clin Immunol; 2009 Dec 19; 124(6):1210-6. PubMed ID: 19910033
    [Abstract] [Full Text] [Related]

  • 12. [Retrospective analysis of omalizumab in patients with severe allergic asthma].
    Padullés Zamora N, Comas Sugrañes D, Méndez Cabaleiro N, Figueras Suriol A, Jodar Masanes R.
    Farm Hosp; 2013 Dec 19; 37(5):399-405. PubMed ID: 24128103
    [Abstract] [Full Text] [Related]

  • 13. Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy.
    Zhu R, Zheng Y, Putnam WS, Visich J, Eisner MD, Matthews JG, Rosen KE, D'Argenio DZ.
    AAPS J; 2013 Apr 19; 15(2):559-70. PubMed ID: 23413101
    [Abstract] [Full Text] [Related]

  • 14. [Anti IgE antibodies for the treatment of difficult asthma].
    Humbert M, Tonnel AB.
    Rev Mal Respir; 2005 Dec 19; 22(6 Pt 1):983-90. PubMed ID: 16222222
    [Abstract] [Full Text] [Related]

  • 15. Longitudinal study of the expression of FcεRI and IgE on basophils and dendritic cells in association with basophil function in two patients with severe allergic asthma treated with Omalizumab.
    Pereira Santos MC, Campos Melo A, Caetano A, Caiado J, Mendes A, Pereira Barbosa M, Branco Ferreira M.
    Eur Ann Allergy Clin Immunol; 2015 Mar 19; 47(2):38-40. PubMed ID: 25781192
    [Abstract] [Full Text] [Related]

  • 16. Anti-IgE and chemotherapy: a critical appraisal of treatment options for severe asthma.
    Walters EH, Walters JA, Wood-Baker R.
    Expert Opin Pharmacother; 2007 Apr 19; 8(5):585-92. PubMed ID: 17376014
    [Abstract] [Full Text] [Related]

  • 17. Severe persistent asthma responsive to off-label use of omalizumab despite high and low levels of total serum IgE.
    Asai N, Ohkuni Y, Komatsu A, Matsunuma R, Nakashima K, Kaneko N.
    J Bras Pneumol; 2011 Apr 19; 37(4):567-70. PubMed ID: 21881749
    [No Abstract] [Full Text] [Related]

  • 18. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
    Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N.
    Pharmacoeconomics; 2012 Nov 01; 30(11):991-1004. PubMed ID: 22950547
    [Abstract] [Full Text] [Related]

  • 19. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G, Piccolo A, Salzillo A, Noschese P, D'Amato M, Liccardi G.
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov 01; 1(3):225-31. PubMed ID: 19075985
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.